Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia

Clinica Chimica Acta

Volumn 366, Issue 1-2, 2006, Pages 185-189

  El Messal, Mariame ^a   Beaudeux, Jean Louis ^b   Drissi, Anas ^c   Giral, Philippe ^b   Chater, Rachid ^a,c   Bruckert, Eric ^b   Adlouni, Ahmed ^c   Chapman, M John ^b  

^a FACULTÉ DES SCIENCES AIN CHOCK   (Morocco)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

Author keywords

Atherosclerosis; Familial hypercholesterolemia; Inflammation; Matrix remodeling; Metalloproteinase

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; GELATINASE B; INTERLEUKIN 18 BINDING PROTEIN; PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; EXTRACELLULAR MATRIX; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFLAMMATION; MALE; MOROCCO; MULTIVARIATE ANALYSIS; PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAMPLE SIZE; SENSITIVITY ANALYSIS; SERUM;

EID: 33644686221     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.09.027     Document Type: Article

References (34)

1. L. Villeger, M. Abifadel, and D. Allard The UMD-LDLR database: additions to the software and 490 new entries to the database Hum Mutat 20 2002 81 87
2. L.F. Soria, E.H. Ludwig, H.R.G. Clarke, G.L. Vega, S.M. Grundy, and B.J. McCarty Association between a specific Apo B mutation and familial defective apoB100 Proc Natl Acad Sci U S A 86 1989 587 591
3. M. Abifadel, M. Varret, and J.P. Rabes Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156
4. M. El Messal, K. Ait Chihab, and R. Chater Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene J Hum Genet 48 2003 199 203
5. J.L. Goldstein, H.H. Hobbs, and M.S. Brown Familial hypercholesterolemia C.R. Scriver A.L. Beaudet W. Sly D. Valle The metabolic and molecular bases of inherited disease 7th ed. 1995 McGraw-Hill New York 1981 2030
6. H. Mabuchi, J. Koizumi, M. Shimizu, and R. Takeda Development of coronary heart disease in familial hypercholesterolemia Circulation 79 1989 225 232
7. R. Ross Atherosclerosis: an inflammatory disease N Engl J Med 340 1999 115 126
8. E. Falk, P.K. Shah, and V. Fuster Coronary plaque disruption Circulation 92 1995 657 671
9. V. Fuster, and A. Lewis Mechanisms leading to myocardial infarction: insights from studies of vascular biology Circulation 90 1994 2126 2146
10. R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s Nature 362 1993 801 809
11. P.M. Ridker Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view Blood Coagul Fibrinolysis 10 1999 9 12
12. M.P. Bevilacqua Endothelial-leukocyte adhesion molecules Annu Rev Immunol 11 1993 767 804
13. H. Li, M.W. Freeman, and P. Libby Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines J Clin Invest 95 1995 122 133
14. P. Libby, G. Sukhova, R.T. Lee, and Z.S. Galis Cytokines regulate vascular functions related to stability of the atherosclerotic plaque Cardiovasc Pharmacol 25 1995 9 12
15. E.L. Filonzi, H. Zoellner, H. Stanton, and J.A. Hamilton Cytokine regulation of granulocytemacrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells Atherosclerosis 99 1993 241 252
16. C.M. Dollery, J.R. McEwan, and A.M. Henney Matrix metalloproteinases and cardiovascular disease Circ Res 77 1995 863 868
17. D.C. Celentano, and W.H. Frishman Matrix metalloproteinases and coronary artery disease: a novel therapeutic target J Clin Pharmacol 37 1997 991 1000
18. Z.S. Galis, G.K. Sukhova, M.W. Lark, and P. Libby Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J Clin Invest 94 1994 2493 2503
19. Z.S. Galis, and J.J. Khatri Matrix metalloproteinases in vascular remodelling and atherogenesis: the good, the bad, and the ugly Circ Res 90 2002 251 262
20. J.L. Beaudeux, P. Giral, E. Bruckert, M. Bernard, M.J. Foglietti, and M.J. Chapman Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia Atherosclerosis 169 2003 139 146
21. C. Rovers, M.G. Netea, and N. de Bont LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia Atherosclerosis 141 1998 99 105
22. Y. Noji, T. Higashikata, A. Inazu Hokuriku NK-104 Study Group Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia Atherosclerosis 163 2002 157 164
23. M.E. Wittekoek, and J.P. Kastelein Familial hypercholesterolemia molecular genetics and clinical expression Atherosclerosis 147 1998 709 712
24. Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simone Broome Register Group Br Med J 303 1991 893 896
25. W.T. Friedewald, F.I. Levy, and D.S. Fredrickson Estimation of the concentration of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge Clin Chem 18 1972 499 509
26. C. Monaco, E. Andreakos, and S. Kiriakidis Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis Proc. Natl Acad Sci U S A 101 2004 5634 5639
27. G.K. Hansson Immune mechanisms in atherosclerosis Arterioscler Thromb Vasc Biol 21 2001 1876 1890
28. P. Ferroni, S. Basili, and G. Davi Platelet activation, inflammatory mediators and hypercholesterolemia Curr Vasc Pharmacol 1 2003 157 169
29. H. Gunduz, R. Akdemir, E. Binak, A. Tamer, N. Keser, and C. Uyan Can serum lipid and CRP levels predict the "severity" of aortic valve stenosis? Acta Cardiol 58 2003 321 326
30. P.M. Moriarty, C.A. Gibson, J. Shih, and M.S. Matias C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis Atherosclerosis 158 2001 495 498
31. S. Van Wissen, M.D. Trip, T.J. Smilde, J. de Graaf, A.F. Stalenhoef, and J.J. Kastelein Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy Atherosclerosis 165 2002 361 366
32. M. Leirisalo-Repo, M. Jaattela, H. Gylling, T.A. Miettinen, and H. Repo Phagocyte function in familial hypercholesterolaemia: peripheral blood monocytes exposed to lipopolysaccharide show increased tumour necrosis factor production Scand J Immunol 32 1990 679 685
33. J.L. Beaudeux, L. Burc, F. Imbert-Bismut, P. Giral, M.J. Chapman, and E. Bruckert Serum pregnancy-associated plasma protein-A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk Arterioscler Thromb Vasc Biol 23 2003 7 10
34. H. Kai, H. Ikeda, and H. Yasukawa Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes J Am Coll Cardiol 32 1998 368 372